Antitope Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Antitope Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011789
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibodies or proteins. Its EpiScreen T cell epitope mapping identifies the exact number and location of T cell epitopes within an antibody or protein. Antitope’s technologies are used in the immunogenicity assessment and protein engineering to develop humanized antibodies and deimmunised proteins. The company also provides services and technologies for the selection, development and manufacturing of biopharmaceuticals based on antibodies and other proteins. Antitope is headquartered in Cambridge, the UK.

Antitope Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Antitope Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antitope Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antitope Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antitope Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Antitope Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Antitope Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 10
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 11
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 12
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 13
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 14
Antitope Enters Into Research Agreement With NeuroPhage Pharma 15
Antitope Enters Into Research Collaboration With Therapure Biopharma 16
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 17
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 18
Antitope Enters Into Co-Development Agreement With IMMIH 19
Antitope Enters Into Research Collaboration With NasVax 20
Cellmid Enters into Agreement with Antitope 21
Licensing Agreements 22
ProtAb Enters into License Agreement with Antitope 22
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 23
Acquisition 24
PolyTherics Acquires Antitope For US$20.7 Million 24
Antitope Ltd – Key Competitors 25
Antitope Ltd – Key Employees 26
Antitope Ltd – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Government and Public Interest 28
Jan 18, 2016: Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Antitope Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Antitope Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antitope Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antitope Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antitope Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Antitope Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 10
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 11
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 12
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 13
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 14
Antitope Enters Into Research Agreement With NeuroPhage Pharma 15
Antitope Enters Into Research Collaboration With Therapure Biopharma 16
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 17
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 18
Antitope Enters Into Co-Development Agreement With IMMIH 19
Antitope Enters Into Research Collaboration With NasVax 20
Cellmid Enters into Agreement with Antitope 21
ProtAb Enters into License Agreement with Antitope 22
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 23
PolyTherics Acquires Antitope For US$20.7 Million 24
Antitope Ltd, Key Competitors 25
Antitope Ltd, Key Employees 26

★海外企業調査レポート[Antitope Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Gunma Bank Ltd:企業の戦略・SWOT・財務分析
    The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • LPP SA (LPP):企業の財務・戦略的SWOT分析
    LPP SA (LPP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Quadrise Fuels International Plc (QFI):石油・ガス:M&Aディール及び事業提携情報
    Summary Quadrise Fuels International Plc (QFI), previously Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multi phase Superfine Atomized Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation …
  • IMI Plc (IMI):石油・ガス:M&Aディール及び事業提携情報
    Summary IMI Plc (IMI) is a manufacturer of valve and fluid technology solutions. The company designs, manufactures and services engineered products that control the precise movement of fluids. It offers critical flow control solutions that enable energy and process industries to operate safely and e …
  • Nichi-Iko Pharmaceutical Co Ltd (4541):企業の財務・戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahis …
  • Jyske Bank A/S:企業の戦略・SWOT・財務情報
    Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report Summary Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cameron International Corporation:石油・ガス:M&Aディール及び事業提携情報
    Summary Cameron International Corporation (Cameron), a subsidiary of Schlumberger Limited specializes in engineering, designing, and manufacturing flow and pressure control technologies for oil and gas industry. The company offers drilling systems, dryaccess deepwater production systems, safety syst …
  • Dover Corporation:企業の戦略・SWOT・財務情報
    Dover Corporation - Strategy, SWOT and Corporate Finance Report Summary Dover Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Akenerji Elektrik Uretim AS (AKENR):企業の財務・戦略的SWOT分析
    Akenerji Elektrik Uretim AS (AKENR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • VINCI Energies:電力:M&Aディール及び事業提携情報
    Summary VINCI Energies S.A. (Vinci), a subsidiary of Vinci SA, is a provider of energy efficiency and renewable energy solutions. The company offers heating, ventilation and air conditioning, electric power, mechanical engineering and information and communications technologies. Vinci operates in mu …
  • United Gulf Bank (B.S.C.)
    United Gulf Bank (B.S.C.) - Strategy, SWOT and Corporate Finance Report Summary United Gulf Bank (B.S.C.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aptuit LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aptuit LLC (Aptuit) is a provider of drug discovery and development services. The company offer wide range of services such as manufacturing, project management, small and large molecules analysis, formulation development, integrated chemistry, API route scouting and process development, con …
  • HSBC Holdings Plc:企業の戦略・SWOT・財務情報
    HSBC Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary HSBC Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Baytex Energy Corp (BTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Baytex Energy Corp (Baytex Energy) is an independent upstream oil and gas company. It conducts the acquisition, development and production of petroleum and natural gas at its properties in the Western Canadian Sedimentary basin and in the Eagle Ford the US. The company’s products include hea …
  • Liberty Mutual Holding Company Inc.:企業の戦略・SWOT・財務情報
    Liberty Mutual Holding Company Inc. - Strategy, SWOT and Corporate Finance Report Summary Liberty Mutual Holding Company Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • CAT Telecom Public Co Ltd:企業の戦略的SWOT分析
    CAT Telecom Public Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Alarko Contracting Group:企業の戦略・SWOT・財務分析
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hanger, Inc. (HNGR):企業の財務・戦略的SWOT分析
    Hanger, Inc. (HNGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hanger, Inc.-医療機器分野:企業M&A・提携分析
    Summary Hanger, Inc. (Hanger) formerly Hanger Orthopedic Group, Inc., is a health care and medical device company. The company along with its subsidiaries offers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions. Hanger is one of the largest owner …
  • Correvio Pharma Corp (CORV):企業の財務・戦略的SWOT分析
    Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆